Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. - Wikidata - awgldk - TriplyDB

Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity.

Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity.

http://www.wikidata.org/entity/Q44770183

about

Drug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical data The transcriptional regulation of the human CYP2C genes Update and new trends in antiemetic therapy: the continuing need for novel therapies.Impact of age, CYP2C9 genotype and concomitant medication on the rate of rise for prothrombin time during the first 30 days of warfarin therapy.Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance)Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.Aprepitant (EMEND): the role of substance P in nausea and vomiting.An approach to evaluating drug-nutrient interactions.Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant.Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients.Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.Aprepitant: drug-drug interactions in perspective.Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting.Pharmacologic management of postoperative nausea and vomiting.Use of high-dose cisplatin with aprepitant in an outpatient setting.Induction of cytochrome P450 enzymes: a view on human in vivo findings.Drug interactions with aprepitant or fosaprepitant: Review of literature and implications for clinical practice.Clinical pharmacology of neurokinin-1 receptor antagonists for the treatment of nausea and vomiting associated with chemotherapy.Aprepitant and fosaprepitant drug interactions: a systematic review.Pharmacokinetic interaction between pazopanib and cisplatin regimen.In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7.Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations Two cases of fatal encephalopathy related to Ifosfamide: an adverse role of aprepitant?Effect of aprepitant on intravenous tacrolimus disposition in reduced intensity hematopoietic stem cell transplantation.Limited sampling strategy in rats to predict the inhibited activities of hepatic CYP3A.Effect of netupitant, a highly selective NK₁ receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone.Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail.Emesis and nausea related to single agent trabectedin in ovarian cancer patients: a sub-study of the MITO15 project.Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant.Persistent drug interaction between aprepitant and warfarin in patients receiving anticancer chemotherapy.Influence of aprepitant on the pharmacodynamics and pharmacokinetics of gliclazide in rats and rabbits.

P2860

Q28084970-1E3D366C-EC7C-476A-ACB1-40453015073B Q33597311-7D36C9E8-6AA9-4BE4-96EB-C5D376E10C47 Q34143667-E8CD586A-6C79-4A4E-8CBB-45E2EA5B5BEE Q34146486-06591309-064B-40CF-AFB2-27ED1509FDA9 Q34570873-48C69B31-DDA0-4263-8EA5-A2C8EE5D1ABC Q35024342-F2302AD8-AFED-45C1-91B8-656D83C06B0A Q35962019-0F5C1E51-488F-4C5B-97C5-7D015C13CE79 Q36284018-76831C28-3DBA-46A8-9D5F-12D671399B5B Q36320632-629EB6A4-56B7-4B99-B58F-B4F1455413EE Q36920404-55426D8E-2C44-4EB3-8D24-3DE43E8D82AB Q37355479-34317235-048B-47AF-9687-E7E85A1C4948 Q37636064-098FC072-4A14-4EF3-9430-C3874067C12A Q37757799-33343EFD-BC23-4372-9A92-6FD91CCDA209 Q37854702-723B28B9-123C-430E-BBAD-2C1195AE185D Q37901057-BF9F83D2-BDEB-40B4-8015-DE7C923A5C7D Q37924902-E5CED6CB-F3D9-437D-AC48-76C742E20A0F Q38057372-DB22390F-35AD-4B59-B05E-D579A66B4B60 Q38752456-682BA9FE-67F6-49B5-AAB7-4FFFA371ABF2 Q39275766-B4A83C88-6E38-41F3-91F0-3D642ABE236B Q39282847-BDCF77CA-F5DA-48BC-8D3C-0A37759AE455 Q40094748-117F1227-34D5-4250-BC0D-A7FFCA8E8A45 Q40600601-2ED909B2-17BE-474B-A89C-A9D5AC4994F6 Q41386264-4C19A28A-5B77-4507-9350-E9139640A950 Q41994672-6A92E4B5-7B98-4278-AB16-9D959242F261 Q45169488-76104905-6992-46DE-AC3F-ABDA040B9DF4 Q46112124-0A2AAE9F-70EF-4489-AF02-0A24C3A7949B Q46530749-EFE31955-DCBB-47EC-B8E4-A27B7AE4101D Q46807641-D793CE1C-3679-46FF-B89F-B7F42A633E1B Q47885855-882C1C42-3D2F-49DE-B4CA-515F414ED87D Q48333205-6F4DF667-F01A-4D07-A673-A9E096560B7C Q53083182-F0022A68-D061-4850-AEF8-BC092522B77F Q55060909-E721A651-FC32-4E38-A317-BE9B02A4F597

P2860

Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity.

http://www.wikidata.org/entity/Q44770183

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Evaluation of potential induct ...... ome P450 3A4 and 2C9 activity.

@en

Evaluation of potential induct ...... ome P450 3A4 and 2C9 activity.

@nl

type

label

Evaluation of potential induct ...... ome P450 3A4 and 2C9 activity.

@en

Evaluation of potential induct ...... ome P450 3A4 and 2C9 activity.

@nl

prefLabel

Evaluation of potential induct ...... ome P450 3A4 and 2C9 activity.

@en

Evaluation of potential induct ...... ome P450 3A4 and 2C9 activity.

@nl

P1433

Q44770183-38A18497-FE6A-47D4-A674-44F08699EF5A

P1476

Q44770183-FC5661F5-F17B-4599-9585-94BEA02FA8CB

P2093

Q44770183-14FE62C2-83FF-4A12-8AC8-77B6DC28327A

Q44770183-2BB6D9A4-8BDB-43DE-AB86-C49B67E2168A

Q44770183-5D15DD17-5BE6-4739-9C87-9A0152DC7C22

Q44770183-8C6D8540-918E-454E-B62A-EBB650F31FF1

Q44770183-A6B31ED1-386F-4B36-BB28-10918CEF57B1

Q44770183-B347A623-5F71-4951-8F7A-9CFDFC8D5080

Q44770183-BEF25459-3034-4DF7-94DC-C88780303E43

Q44770183-F29E262A-A579-410D-8A5D-64D63F4EB7D9

P2860

Q44770183-16F09783-4086-4DCA-A72B-8D4D95D4D647

Q44770183-1B778DD3-F952-4CAF-A9DA-BF1FC22784F9

Q44770183-5B41AAD1-6C6B-4ABD-9DE7-8DD34B032011

Q44770183-BA5C64DD-CCF9-49DF-B371-FAA963A499B2

Q44770183-C1523007-08DA-4BCA-854D-7F71124F2338

Q44770183-C456B421-DB3D-464A-9991-258551EB9E2A

Q44770183-E14C1428-D552-42F0-93B9-6D4B89EFF70B

P304

Q44770183-02CDF592-84E3-40D2-8C7D-CC4F909CE830

P31

Q44770183-695EABBA-900C-4054-9E0A-21BC78A99F80

P356

Q44770183-C7EA073E-08C0-4B39-BD4E-65A98FD60458

P433

Q44770183-B1A6CE5A-EE78-457D-AC25-AF238A436B43

P478

Q44770183-2297F658-A283-405E-A5A5-A57D03FC99B4

P577

Q44770183-969841EC-901E-4C21-910F-19E7FCFE2164

P698

Q44770183-4E56631D-0122-4396-BC6B-965586C36BE4

P356

0091270003262950

P1433

The Journal of Clinical Pharmacology

P1476

Evaluation of potential induct ...... ome P450 3A4 and 2C9 activity.

@en

P2093

Anup K Majumdar

http://www.w3.org/2001/XMLSchema#string

Craig R Shadle

http://www.w3.org/2001/XMLSchema#string

Cynthia Gargano

http://www.w3.org/2001/XMLSchema#string

Judith K Evans

http://www.w3.org/2001/XMLSchema#string

Kevin J Petty

http://www.w3.org/2001/XMLSchema#string

Robert A Blum

http://www.w3.org/2001/XMLSchema#string

Thomas E Bradstreet

http://www.w3.org/2001/XMLSchema#string

Yih Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.

Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.

The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.

Rifampin drastically reduces plasma concentrations and effects of oral midazolam.

Interaction of sodium warfarin and rifampin. Studies in man.

P304

215-223

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0091270003262950

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P577

2004-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14973304

http://www.w3.org/2001/XMLSchema#string